These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22322254)

  • 21. Transcriptome modeling and phenotypic assays for cancer precision medicine.
    Jeong E; Moon SU; Song M; Yoon S
    Arch Pharm Res; 2017 Aug; 40(8):906-914. PubMed ID: 28766239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathology in therapeutics: where are we now, and where are we going?
    Harrison DJ; Faratian D
    Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
    [No Abstract]   [Full Text] [Related]  

  • 23. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
    Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
    Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
    [No Abstract]   [Full Text] [Related]  

  • 24. Now's the time to find biomarkers on purpose.
    Auman JT; McLeod HL
    Ann Oncol; 2010 Feb; 21(2):193-194. PubMed ID: 20047974
    [No Abstract]   [Full Text] [Related]  

  • 25. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
    Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
    Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision Medicine and Targeted Therapies in Breast Cancer.
    Greenwalt I; Zaza N; Das S; Li BD
    Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
    Alymani NA; Smith MD; Williams DJ; Petty RD
    Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Cancer: Genetics and the Role of Precision Medicine.
    Li CC; Shen Z; Bavarian R; Yang F; Bhattacharya A
    Surg Oncol Clin N Am; 2020 Jan; 29(1):127-144. PubMed ID: 31757309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision cancer medicine: where to target?
    Yu Q; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154
    [No Abstract]   [Full Text] [Related]  

  • 36. Individualizing Care: Management Beyond Medical Therapy.
    Cristoferi L; Nardi A; Invernizzi P; Mells G; Carbone M
    Surg Oncol Clin N Am; 2020 Jan; 29(1):87-103. PubMed ID: 31757316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Precision medicine from experimental to clinical applications in oncology].
    Normanno N
    Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges ahead for companion diagnostics.
    Schmidt C
    J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.